Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Epigenetic regulation of FLT3 by ZNF384-fusion protein

ABSTRACT: Profiling global gene expression in large ALL cohorts, we identified unique over-expression of FLT3 in ZNF384-rearranged ALL, consistently across cases harboring different fusion partners with ZNF384. Mechanistically, we discovered an intergenic enhancer element at the FLT3 locus that is exclusively activated in ZNF384-rearranged ALL, with the enhancer-promoter looping directly mediated by the fusion protein. There was also a striking global enrichment of active enhancers within ZNF384 binding sites across the genome in ZNF384-rearranged ALL cells.

ORGANISM(S): Homo sapiens

PROVIDER: GSE197890 | GEO | 2022/08/11

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

ZNF384 fusion oncoproteins drive lineage aberrancy in acute leukemia

Project description:ZNF384-rearranged fusion oncoproteins (FO) define a subset of lineage ambiguous leukemias, but the mechanistic role of ZNF384 FO in leukemogenesis and lineage ambiguity is poorly understood. Here, using viral expression in mouse and human hematopoietic stem and progenitor cells (HSPCs) and a Ep300-Zfp384 mouse model we show that ZNF384 FO promote hematopoietic expansion, myeloid lineage skewing, and self-renewal. In mouse HSPCs, concomitant lesions such as NRASG12D, were required for fully penetrant leukemia, whereas expression of ZNF384 FO drove development of B/myeloid leukemia in human HSPCs, with sensitivity of human ZNF384r leukemia to FLT3 inhibition in vivo. Mechanistically, ZNF384 FO occupy a subset of predominantly intragenic/enhancer regions with increased histone 3 lysine acetylation suggesting enhancer function. These data define a paradigm for FO-driven lineage ambiguous leukemia, in which expression in HSPCs results in deregulation of lineage-specific genes and hematopoietic skewing, progressing to full leukemic transformation in the presence of proliferative stress.

2022-03-16 | PXD028481 | Pride

RNA-sequencing to investigate transcriptional changes caused by ZNF384 fusion proteins in murine pre-B cells

Project description:RNA-sequencing was performed on Arf-/- pre-B cell expressing either wild-type ZNF384, TAF15-ZNF384, or TCF3-ZNF384. We found that pre-B cells that express ZNF384 fusion proteins have a gene expression profile similar to patients with ZNF384-rearranged leukemia.

2018-10-18 | GSE112558 | GEO

ChIP-sequencing to investigate occupancy of wild-type and fusion ZNF384 proteins in murine pre-B cells

Project description:We report the changes in chromatin occupancy between HA-tagged wild-type ZNF384 and the two leukemogenic fusion proteins, TAF15-ZNF384, and TCF3-ZNF384, in Arf-/- pre-B cells. Using ChIP-sequencing we found that 2298 peaks have new or increased binding while 495 peaks have decreased or lost binding of the fusion proteins compared to wild-type ZNF384.

2018-10-18 | GSE112560 | GEO

ZNF384 fusion oncoproteins drive lineage aberrancy in acute leukemia [ChIP-seq]

Project description:We report changes in chromatin occupancy dependent on TCF3-ZNF384 splicing isoform usage. The isoform including exon 8, which encodes 2 zinc finger domains, has increased binding near genes important for nomal hematopoiesis. We report no global changes in H3K27Ac upon expression of ZNF384 fusions but 47 loci with increased H3K27Ac.

2022-08-31 | GSE181617 | GEO

ZNF384 fusion oncoproteins drive lineage aberrancy in acute leukemia [HiChIP]

Project description:We report no global changes in H3K27Ac upon expression of ZNF384 fusions but 47 loci with increased H3K27Ac. Therefore we performed HiChIP H3K27Ac to determine if those loci are enhancers. We did not observe any differential looping.

2022-08-31 | GSE181498 | GEO

MLL-fusion-mediated activation of FLT3-ITD lesions promotes leukemogenesis

Project description:MLL-rearranged (MLL-r) leukemia, a particularly intractable disease, depends on DOT1L-mediated H3K79 methylation. Depletion of this transcriptionally activating mark by DOT1L loss-of-function or high concentrations of highly-specific inhibitor pinometostat (≥1 mM EPZ5676) leads to the downregulation of HOXA9 and MEIS1, and consequent reduction leukemia survival. . Yet, some MLL-r cell lines are inexplicably susceptible to low-dose pinometostat, below the threshold for downregulating these canonical oncogenic drivers. Here we define alternative pathways disrupted by low-dose pinometostat (10 nM), a concentration that reduces proliferation of the MLL-r MV4;11 cell line without affecting HOXA9 and MEIS1 expression and downregulates a subset of MLL-fusion targets including FLT3, one of the most commonly mutated genes in leukemia. Using quantitative ICeChIP-seq, we observe profound H3K79me2 depletion at downregulated MLL-r targets, with resulting increases in transcriptionally activating H3K4me3 at promoters and reductions in repressive H3K27me3. The presence of co-occurring activating FLT3 mutations, portend greater cytotoxicity to inhibitor treatment. Although downregulation of polycomb components modestly contributes to reductions in proliferation, overexpression of constitutively active STAT5A, a target of FLT3-ITD-signalling, nearly completely rescues proliferation, accounting for the bulk of cytotoxicity from H3K79me2 depletion. We also observe a dependence of FLT3-STAT5A signaling on MLL function, suggesting that the FLT3 locus is exquisitely sensitivity to both H3K79me2 and H3K4me3 depletion and arguing that combinations of DOT1L, MLL1 and FLT3 inhibitors should be explored for treating the ~30% of all leukemias that carry FLT3 mutations.

2021-07-15 | GSE162441 | GEO

ZNF384 fusion oncoproteins drive lineage aberrancy in acute leukemia [RNA-Seq]

Project description:RNA-seq of multiple models of ZNF384-rearrangments (transplanted human CD34 cells and transplanted mouse lineage negative cells) to determine differentially expressed genes.

2022-08-31 | GSE181532 | GEO

ZNF384 fusion oncoproteins drive lineage aberrancy in acute leukemia [RNA-seq 2]

Project description:To investigate usage of exon 8 in ZNF384 in different myeloid/lymphoid populations from MPAL/BALL PDX and cell lines

2022-08-31 | GSE191028 | GEO

ZNF384 fusion oncoproteins drive lineage aberrancy in acute leukemia [scRNA-Seq]

Project description:Expression of ZNF384 fusions results in lineage abberancy and leukemia development. Here we report the gene expression changes that occur in the hematopoietic system when Ep300-Zfp384 is expressed in a transgenic mouse model.

2022-08-31 | GSE181495 | GEO

MLL-fusion-mediated activation of FLT3-ITD lesions promotes leukemogenesis

Project description:MLL-fusion-mediated activation of FLT3-ITD lesions promotes leukemogenesis

| PRJNA681873 | ENA